


WHAT IS CLAIMED IS:

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof,

wherein

Y is CHR^5 or NR^6 ;

Z is CH , CR^3 , or N ;

n is 0, 1, 2, or 3;

R^1 is $-O-L-N(R^7)_2$ or optionally substituted, four-membered, saturated *N*-heterocyclyl;

R^2 is C_{1-3} alkyl;

each R^3 is independently halogen or optionally substituted C_{1-3} alkyl;

R^4 is optionally substituted alkyl;

R^5 is hydrogen, optionally substituted C_{1-3} alkyl, or benzyloxy;


R^6 is optionally substituted C_{1-3} alkyl;

each R^7 is independently H or optionally substituted C_{1-3} alkyl; and

L is optionally substituted ethylene.

- 2 The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 1.

- 3 The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IA):




or a pharmaceutically acceptable salt thereof.

- 4 The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^3 is halogen.

- 5 The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein halogen is fluorine.

- 6 The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IB):



or a pharmaceutically acceptable salt thereof.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is $-O-L-N(R^7)_2$.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein one R^7 is H, and the remaining R^7 is optionally C_{1-3} alkyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein at least one R^7 is isopropyl.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl, ethyl, or isopropyl.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^4 is methyl.

14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein Y is CHR^5 .

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is hydrogen.

16. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is optionally substituted C_{1-3} alkyl


17. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is benzyloxy.

18. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein Y is NR^6 .

-
- Chemical structures of 11 compounds (1-11) used in the study. The structures are arranged in a grid. Compounds 1-10 are derivatives of a quinoline core with a 4-fluoro group and a 1-methyl-4-oxo-4,5,6,7-tetrahydrocyclobuta[b]quinolin-2-yl group. The side chain at the 2-position of the quinoline is a 4-(isopropylamino)ethoxy group. Compounds 1-10 are shown in two rows of five. Compound 11 is shown at the bottom. The structures are labeled 1 through 11.


59

22. A compound of the following structure:




or a pharmaceutically acceptable salt thereof.

23. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

24. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising the compound of any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

26. A method of treating an oncological disease, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 25 to a patient in need thereof.

27. The method of claim 26, wherein the patient is receiving radiotherapy.

28. The method of claim 27, wherein the compound or the pharmaceutical composition is administered to the patient concomitantly with the radiotherapy.

29. The method of claim 27, wherein the compound or the pharmaceutical composition is administered to the patient before radiotherapy.

30. The method of claim 27, wherein the compound or the pharmaceutical composition is administered to the patient after radiotherapy.
31. The method of any one of claims 27 to 30, wherein the radiotherapy comprises external, internal, brachytherapy, or systemic exposure.
32. The method of any one of claims 27 to 31, wherein the radiotherapy comprises administering an antibody radionuclide conjugate.
33. The method of any one of claims 26 to 32, wherein the patient is receiving an anti-tumor agent.
34. The method of claim 33, wherein the anti-tumor agent is cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, calicheamicin, or a PARP inhibitor.
35. The method of claim 34, wherein the anti-tumor agent is an anti-tumor biological agent or an anti-tumor immunotherapeutic agent.
36. The method of any one of claims 33 to 35, wherein the compound or the pharmaceutical composition is administered to the patient concomitantly with the anti-tumor agent.
37. The method of any one of claims 33 to 35, wherein the compound or the pharmaceutical composition is administered to the patient before the anti-tumor agent.
38. The method of any one of claims 33 to 35, wherein the compound or the pharmaceutical composition is administered to the patient after the anti-tumor agent.
39. The method of any one of claims 26 to 38, wherein the oncological disease is a brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, cancer of the mouth, hepatocellular cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, sarcomas, testicular cancer, urothelial cancer, vulvar cancer, or Wilm's tumor.
40. The method of any one of claims 26 to 38, wherein the oncological disease is a breast cancer, lung cancer, head and neck cancer, pancreatic cancer, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastatic liver lesions, melanoma, bone sarcoma, soft tissue sarcoma, endometrial cancer, cervical cancer, prostate cancer, or Merkel cell carcinoma.